Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans.

Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans.
复制标题

DOI:
10.2147/ceg.s26297
复制
发表时间:
2011
影响因子:
2.4
通讯作者:
Kuwano H
Kuwano H
中科院分区:
其他
文献类型:
--
作者:
Ohno T;Yanai M;Ando H;Toyomasu Y;Ogawa A;Morita H;Ogata K;Mochiki E;Asao T;Kuwano H

文献摘要

被引文献

相似文献

本研究的目的是探讨利空石对人类胃饥饿素分泌和顺铂诱导的厌食症的影响。本研究采用交叉设计,将10例不可切除或复发的胃癌患者随机分为两组。A组(n = 5)在第一个化疗疗程开始服用力健shito (2.5 g,每日3次,口服),随后进行第二个疗程,不服用力健shito。B组(n = 5)逆序治疗。所有患者均采用S-1 +顺铂联合化疗。主要终点为口服摄取量,以及厌食、恶心和呕吐的量表类别;次要终点包括血浆酰化胃饥饿素浓度。在Rikkunshito-on期,顺铂未引起血浆中酰化胃饥饿素浓度的降低。立身期的平均口服摄取量显著大于立身期,厌食症的等级显著低于立身期。立kunshito似乎可以预防顺铂引起的厌食症,从而有效地预防顺铂化疗,患者可以按计划继续治疗。
The aim of this study was to investigate the effects of Rikkunshito on ghrelin secretion and on cisplatin-induced anorexia in humans. The study was performed as a crossover design, and ten unresectable or relapsed gastric cancer patients were randomly divided into two groups. Group A (n = 5) was started on Rikkunshito (2.5 g three times daily, orally) from the first course of chemotherapy and followed by a second course without Rikkunshito. A treatment with reversed order was performed for Group B (n = 5). All patients received combined chemotherapy with S-1 plus cisplatin. The primary endpoint was the amount of oral intake, and the categories of scales of anorexia, nausea, and vomiting; secondary endpoints included the plasma concentration of acylated ghrelin. In the Rikkunshito-on period, no decrease of the plasma concentration of acylated ghrelin induced by cisplatin was observed. The average oral intake in the Rikkunshito-on period was significantly larger than that in the Rikkunshito-off period, and the grade of anorexia was significantly lower in the Rikkunshito-on period than in the Rikkunshito-off period. Rikkunshito appeared to prevent anorexia induced by cisplatin, resulting in effective prophylactic administration of chemotherapy with cisplatin, and patients could continue their treatments on schedule.